Disease Spotlight
Agitation in Alzheimer's Dementia

Test Your Knowledge

Did you know?

Peer to Peer Insights
Profile Image
  • Add Media
  • Saved

10mo
Future Therapeutic Strategies for Alzheimer's Disease: Focus on Behavioral and Psychological Symptoms - PubMed

Future Therapeutic Strategies for Alzheimer's Disease: Focus on Behavioral and Psychological Symptoms - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39518892/

Alzheimer's disease (AD) is a progressive, degenerative brain disorder that impairs memory and thinking skills, leading to significant economic and humanistic burdens. It is associated with various neuropsychiatric symptoms (NPS)...

This review highlights emerging therapies for neuropsychiatric symptoms in Alzheimer’s disease, focusing on agitation, aggression, and psychosis, and explores novel mechanisms and targets beyond traditional cognitive approaches.

  • Saved

10mo
Does an Audio Wearable Lead to Agitation Reduction in Dementia: The Memesto AWARD Proof-of-Principle Clinical Research Study - PubMed

Does an Audio Wearable Lead to Agitation Reduction in Dementia: The Memesto AWARD Proof-of-Principle Clinical Research Study - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/40034447/

www.clinicaltrials.gov. NCT05153161. First posted December 10, 2021.

https://pubmed.ncbi.nlm.nih.gov/40034447/

This study investigates the Memesto wearable audio device for reducing agitation in Alzheimer's and related dementias, finding a 30% reduction in agitation in 67% of participants after 10 weeks

  • Saved

10mo
Brexpiprazole: A new option in treating agitation in Alzheimer's dementia-Insights from transgenic mouse models

Brexpiprazole: A new option in treating agitation in Alzheimer's dementia-Insights from transgenic mouse models

Source : https://pmc.ncbi.nlm.nih.gov/articles/PMC11544443/

Brexpiprazole is the first FDA‐approved treatment for agitation associated with dementia due to Alzheimer's disease. Agitation in Alzheimer's dementia (AAD) occurs in high prevalence and is a great burden for...

Brexpiprazole reduced aggression and nocturnal hyperactivity in Alzheimer's disease mouse models, supporting its clinical efficacy for treating agitation in Alzheimer’s dementia and providing translational insights into behavioral symptom management.

  • Saved

10mo
Dementia after Ischemic Stroke, from Molecular Biomarkers to Therapeutic Options - PubMed

Dementia after Ischemic Stroke, from Molecular Biomarkers to Therapeutic Options - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39063013/

Ischemic stroke is a leading cause of disability worldwide. While much of post-stroke recovery is focused on physical rehabilitation, post-stroke dementia (PSD) is also a significant contributor to poor functional...

https://pubmed.ncbi.nlm.nih.gov/39063013/

Post-stroke dementia (PSD) impacts recovery after ischemic stroke. Current predictive tools are limited; emerging biomarkers and therapies target cognitive decline, emphasizing the need for continued research into functional outcomes.

  • Saved

10mo
Advancing Neurology: New insights in MS, neurodegeneration, and recovery strategies from AAN 2025

At the 2025 American Academy of Neurology (AAN) Annual Meeting, Dr. Paul George, Science Chair of AAN and Professor at Stanford, highlighted a shift toward a more treatment-driven era in neurology. presentations included emerging biomarkers for Alzheimer’s and Parkinson’s, along with neuromodulation strategies aimed at enhancing brain recovery—insights that may help HCPs refine diagnostic and therapeutic approaches. Dr. Robert Fox, Staff Neurologist at the Mellen Center for MS, presented HERCULES trial data showing Talabrutinib slowed progression in non-relapsing secondary progressive MS—the first to do so—while noting the need for liver safety monitoring.